Kissei Pharmaceutical Co., Ltd.
- Country
- 🇯🇵Japan
- Ownership
- Public
- Established
- 1946-08-09
- Employees
- 1.7K
- Market Cap
- -
- Website
- http://www.kissei.co.jp
A Late Phase II Clinical Trial of KDT-3594 in Patients With Parkinson's Disease
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Target Recruit Count
- 150
- Registration Number
- NCT06722729
- Locations
- 🇯🇵
Research Site, Multiple Locations, Japan
An Early Phase 2 Clinical Study of KSP-0243
- First Posted Date
- 2023-04-26
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT05831670
- Locations
- 🇯🇵
Research Site, Multiple Locations, Japan
A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia and Pain
- Conditions
- Interventions
- First Posted Date
- 2022-07-06
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Target Recruit Count
- 78
- Registration Number
- NCT05445167
- Locations
- 🇯🇵
Clinical Research Site, Multiple Locations, Japan
A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia
- Conditions
- Interventions
- First Posted Date
- 2022-06-30
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Target Recruit Count
- 264
- Registration Number
- NCT05440383
- Locations
- 🇯🇵
Clinical Resarch Site, Multiple Locations, Japan
A Clinical Study of KDT-3594 in Japanese Patients With Early Parkinson's Disease
- First Posted Date
- 2021-04-30
- Last Posted Date
- 2022-05-11
- Lead Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Target Recruit Count
- 7
- Registration Number
- NCT04867551
- Locations
- 🇯🇵
Research Site, Multiple Locations, Japan
A Phase III Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus.
- First Posted Date
- 2021-01-15
- Last Posted Date
- 2023-07-17
- Lead Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Target Recruit Count
- 178
- Registration Number
- NCT04711603
- Locations
- 🇯🇵
Research Site, Multiple Locations, Japan
Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain
- Conditions
- Interventions
- First Posted Date
- 2020-05-01
- Last Posted Date
- 2023-01-13
- Lead Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT04372121
- Locations
- 🇺🇸
Applied Res Center of Ar / Id # 735, Little Rock, Arkansas, United States
🇺🇸Dr. David I. Lubetkin, LLC / ID # 703, Boca Raton, Florida, United States
🇺🇸HCWC dba DiscoveryClinical Trials / ID # 771, Dallas, Texas, United States
Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain (EDELWEISS 6)
- Conditions
- Interventions
- First Posted Date
- 2020-04-06
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Target Recruit Count
- 356
- Registration Number
- NCT04335591
- Locations
- 🇵🇱
Specjalistyczny Gabinet Lekarski Krzysztof Dynowski / ID # 401, Warsaw, Poland
🇺🇸Universal Axon - Homestead, LLC/ ID # 620, Homestead, Florida, United States
🇺🇸Stedman Clinical Trials/ ID # 612, Tampa, Florida, United States
A Clinical Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788
- First Posted Date
- 2019-10-18
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Target Recruit Count
- 34
- Registration Number
- NCT04132050
- Locations
- 🇯🇵
Research Site, Multiple Locations, Japan
Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain.
- Conditions
- Interventions
- First Posted Date
- 2019-06-20
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Target Recruit Count
- 486
- Registration Number
- NCT03992846
- Locations
- 🇺🇸
Wellington Anti-Aging, LLC/ ID # 613, Loxahatchee Groves, Florida, United States
🇦🇹AKH Vienna University of Medicine Vienna / ID # 101, Vienna, Austria
🇨🇿MUDr Jan Drahonovsky, Ustav pro peci o matku a dite/ ID #163, Praha 4, Czechia